ASCO 2022 | Patient eligibility in the AMEERA-6 trial of amcenestrant

Thomas Meyskens, MD, PhD, EORTCKU Leuven, Leuven, Belgium, comments on which groups of patients will be eligible to participate in the phase III AMEERA-6 trial (NCT05128773), which will assess amcenestrant, a selective estrogen receptor degrader (SERD), in patients with HR-positive early breast cancer who discontinued aromatase inhibitors due to toxicity. Patients can be enrolled regardless of HER2 status, as well as ones who have previously received CDK 4/6 inhibitors. This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.